Effects of Ruxolitinib Cream in Patients With Atopic Dermatitis With Head and/or Neck Involvement

Eric Simpson,Kang Sun,Robert Bissonnette,Jonathan Silverberg,May Venturanza,Michael Kuligowski

doi:10.25251/skin.5.supp.67

Abstract

N/A

Highlights

● Atopic dermatitis (AD) is a highly pruritic inflammatory skin disease that often involves the head and/or neck (HN)1,2
● There is a need for well-tolerated treatments that can be used long term on body regions that are prone to irritation/burning and to side effects from topical steroid use, such as the face3
● Pooled efficacy at Week 8 was assessed by achievement of the following endpoints in patients with HN involvement at baseline and the overall population:

Summary

Introduction

● Atopic dermatitis (AD) is a highly pruritic inflammatory skin disease that often involves the head and/or neck (HN). ● There is a need for well-tolerated treatments that can be used long term on body regions that are prone to irritation/burning and to side effects from topical steroid use, such as the face. ● In two phase 3 randomized studies of identical design (TRuEAD1 [NCT03745638] and TRuE-AD2 [NCT03745651]), ruxolitinib cream, a topical selective inhibitor of Janus kinase (JAK) 1/JAK2, demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD4

Study Design and Patients

Results

Conclusions

Disclosures